Navigation Links
Robotic ultrasound gives surgeon more direct control in mapping and removing kidney cancers

DETROIT While the use of ultrasound to identify tumors during kidney cancer surgery is gaining acceptance, a research team at Henry Ford Hospital has successfully taken it a step further by showing an added benefit when the procedure is done robotically.

Simply put, the kidney surgeon who performs the ultrasound robotically has direct control over the painstaking procedure instead of having to rely on an assistant for part of the task.

The researchers compared the robotic ultrasound probe to the same procedure using a laparoscopic ultrasound probe, which requires an assistant to guide the ultrasound probe for the surgeon. At the end of the study, the researchers found comparable results between the two methods.

The paper has been accepted by the Journal of Endourology.

"Besides giving the surgeon autonomy, the robotic ultrasound probe is more easily manipulated than the laparoscopic probe when measuring the tumor from certain angles," said Craig Rogers, M.D., a urologist at Henry Ford Hospital's Vattikuti Urology Institute and senior author of the study. "This can reduce the need to move the kidney to gain better position.

"While our study showed comparable results from both methods of mapping and measuring kidney cancers, the robotic ultrasound probe enables the precision of a robotic instrument as well as direct surgeon control."

The surgical procedure studied used in each case studied by the researchers was robotic partial nephrectomy, or RPN, in which only the diseased part of a cancerous kidney is removed by a surgeon-controlled robot instead of traditional open surgery in which the entire kidney is removed.

They collected data from 75 consecutive RPN procedures using a laparoscopic ultrasound probe and 75 consecutive RPNs using a robotic ultrasound probe.

"Both groups had similar tumor characteristics, operating times and other factors, and their outcomes were similar," Dr. Rogers says. "There was no statistically significant difference in measured variables between groups when controlling for tumor size and complexity. So the robotically controlled ultrasound probe performed on-par with traditional ultrasound, but with the added benefit of direct surgeon control and precision.

All patients in both study groups were found to be cancer-free during follow up examinations at a mean of 25.7 months for the laparoscopic group and 10.2 months for the robotic group.

"We helped pioneer both the development and utilization of this robotic ultrasound probe right here at Henry Ford Hospital" says Dr. Rogers. "This is another advance in technology to help us with minimally invasive cancer surgery."


Contact: Dwight Angell
Henry Ford Health System

Related medicine news :

1. Da Vinci Lawsuit News: Bernstein Liebhard LLP Comments on Report Detailing Rise in Robotic Surgery
2. Mercy Takes Leadership Role in Use of Medical Technology, Offering IORT for Breast Cancer Patients and New National Institute of Robotic Surgery at Mercy
3. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications
4. Da Vinci Lawsuit News: Bernstein Liebhard LLP Comments on Recommendations in Newly Published Study to Reduce Robotic Surgery Complications
5. Johns Hopkins surgeons among the first in the country to perform a robotic single-site hysterectomy
6. Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership
7. Robotic transplant an option for obese kidney patients
8. Florida Hospital Tampa Joins an Elite Group of Hospitals Across the United States Offering Fully Robotic Whipple Surgery
9. Robotic Surgery Update: Intuitive Surgical Issues Urgent Medical Device Warning Notification
10. Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to a Training Specialist Who Said She Taught Doctors How to Use the Robot—Not Operate on Patients
11. Da Vinci Robotic Surgery Lawsuit News: Bernstein Liebhard LLP Comments on New Study Evaluating Robotic Surgery Training Methods
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... ... 01, 2015 , ... McLean, VA., December 1, 2015 - ... per sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT ... software engineering, infrastructure, as well as operations and sustainment support to the NGA’s ...
(Date:12/1/2015)... Auburn, CA (PRWEB) , ... December 01, 2015 ... ... software and clinical solutions for the care management and population health arenas, is ... on providing clinical and cost containment services, has successfully implemented the ACUITY Complete ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015   Nottingham Spirk , ... announced the publication of a free whitepaper ... Medical Market". The whitepaper gives medical product companies, ... penetrating this lucrative segment. Nottingham Spirk ... to manage their own health, save money (i.e., ...
(Date:12/1/2015)... 2015 Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... Conference in New York.  The public is ... a webcast on the Array BioPharma website. ... --> , --> ...
(Date:12/1/2015)... , BANGALORE, India and ... N.V. (NASDAQ, TASE: MYL) today announced that it expects ... and for developing country markets funded by international donors, ... mg + Efavirenz 400 mg) for $99 per patient, ... Initiative (CHAI) to develop TLE400. The significantly reduced price ...
Breaking Medicine Technology: